Kraft Heinz Co vs Summit Therapeutics Inc — how do they compare? Kraft Heinz Co trades at $24.53 (market cap $29.23B), while Summit Therapeutics Inc trades at $15.22 (market cap $12.06B). The key difference: Kraft Heinz Co is far larger — about 2.4× Summit Therapeutics Inc's market cap, and Kraft Heinz Co pays a 6.49% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| KHC | SMMT | |
|---|---|---|
Market Cap | $29.23B | $12.06B |
Sector | Consumer Staples | Health |
52-Week High | $28.06 | $26.98 |
52-Week Low | $21.21 | $12.55 |
Enterprise Value | $45.55B | $11.39B |
Dividend Yield | 6.49% | — |
Signals from Pluang's Aura AI — not financial advice
Kraft Heinz (KHC) trades at $24.36, down 2.29% today, with a bearish technical signal and mixed fundamentals. Recent Q2 2026 earnings beat estimates, but net income margin is negative at -13.64%. The company maintains a $0.40 quarterly dividend, while analyst consensus is mostly Hold. Cash flow from operations improved to $4.46B in 2025, though revenue declined to $24.94B.
Outlook remains cautious due to profit declines and competitive pressures, offset by a low P/E of 13.04 and strategic investments. Key risks include earnings sustainability and high debt. The stock presents value potential but requires monitoring of turnaround execution under CEO Cahillane's strategy.
Summit Therapeutics (SMMT) trades at $15.42, up 3.7% with a bullish technical signal. The company shows negative profitability with ROE at -192.5% and net loss of $1.08B for 2025, but maintains positive analyst sentiment with 14 buy ratings and a $27.90 consensus price target. Recent developments include FDA review of ivonescimab with a November 2026 decision date and expansion into bladder cancer trials.
The investment case hinges on ivonescimab's regulatory approval potential, offering significant upside if successful. However, substantial risks include ongoing losses, cash burn requiring financing, and regulatory uncertainty. Current technical strength suggests momentum, but fundamental challenges require careful risk assessment for speculative biotech investors.
Trailing returns across standard periods
In July 2015, Kraft merged with Heinz to create the third-largest food and beverage manufacturer in North America behind PepsiCo and Nestle and the fifth-largest player in the world. Beyond its namesake brands, the combined firm's portfolio includes Oscar Mayer, Velveeta, and Philadelphia. Outside North America, the firm's global reach includes a distribution network in Europe and emerging markets that drive around one fifth of its consolidated sales base, as its products are sold in more than 190 countries and territories.
Read more on KHC →Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →